1334675-29-4

Basic information

• Product Name: 2-(3,4,5-trimethoxyphenyl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxoethyl]amide
• Synonyms: 2-(3,4,5-trimethoxyphenyl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxoethyl]amide
• CAS NO: 1334675-29-4
• Molecular Weight: 594.743
• Mol File: 1334675-29-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(3,4,5-trimethoxyphenyl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxoethyl]amide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4,5-trimethoxyphenyl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxoethyl]amide(1334675-29-4)
• EPA Substance Registry System: 2-(3,4,5-trimethoxyphenyl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxoethyl]amide(1334675-29-4)

Safety Data

• Hazardous Substances Data: 1334675-29-4(Hazardous Substances Data)

Upstream product

• 1334674-98-4 [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 
• 1184926-29-1 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine 
• 1334675-00-1 (R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl-ammonium trifluoroacetate 
• 182163-96-8 3,4,5-trimethoxyphenylboronic Acid 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 

Downstream Products

• 1334674-45-1 2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxoethyl]amide 

Relevant articles and documents

Pyrrolopyrazine Kinase Inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.